bThe morbidity of high-dose chemotherapy has been considerably reduced by the use of autologous peripheral blood progenitor cell reinfusion. Most studies have used myeloid colony-stimulating factors after stem cel reinfusion, making it difficult to determine the relative contribution of each of these variables to the early recovery of blood ceUls. The financial implications of colony-stimulating factor use are an area of concern as dose intensification in chemosensitive malignancies is increasingly employed. We have studied 19 consecutive patients receiving high-dose chemotherapy with and without filgrastim (Amgen, granulocyte colonystimulating factor, G-CSF) after stem ceUl infusion to examine its effect on the kinetics of blood cell recovery, the complications of myelosuppression and the associated costs. Analysis of the two treatment groups reveals that administration of filgrastim l10g kg-' day-' following stem cell reinfusion does not further accelerate haemopoietic recovery, fails to reduce the incidence of neutropenic fever or antibiotic usage and significantly increases the cost of the procedure. The results of this study do not support the routine use of filgrastim after high-dose chemotherapy and peripheral blood stem cell reinfusion.
The reinfusion of peripheral blood stem cells (PBSCs) following high-dose chemotherapy to accelerate haemopoietic reconstitution is now standard practice in many centres (Gianni et al., 1990; Kessinger & Armitage, 1991; Sheridan et al., 1992) . Several groups have reported reduced durations of thrombocytopenia with PBSC rescue compared with autologous bone marrow transplantation. There have, however, been some reports of patients with acute myeloid leukaemia (AML) receiving purged bone marrow having better diseasefree survival than those receiving peripheral stem cell autografts (Korbling et al., 1991) . It is important to administer sufficient stem cells for engraftment and most centres now recognise a threshold number of reinfused colony-forming unit-granulocyte/macrophage (CFU-GM) cells kg-' to ensure haemopoietic reconstitution (To et al., 1986; Reiffers et al., 1988 Siena et al., 1989; Socinski et al., 1988 Although this is a small study, the results suggest that the administration of filgrastim after PBSC transfusion fails to further accelerate haemopoietic reconstitution, reduce the morbidity of the procedure or reduce the duration of hospitalisation. Importantly, its use significantly increases the cost of the procedure. The failure of filgrastim to significantly accelerate neutrophil recovery contradicts the results of Spitzer et al. (1993) , who studied a similar number of patients but found that a combination of G-CSF and GM-CSF encouraged earlier neutrophil recovery. However, the authors found that administration of growth factors after PBSC infusion made no difference to the duration of hospital stay or fever, results that concur with the findings in our study. The authors make no comment on the use of antibiotics or cost of the procedure. So far there have been no published randomised studies comparing haemopoietic reconstitution following high-dose chemotherapy and PBSC rescue, with and without myeloid growth factors. Although a relatively small number of patients were included in our analysis, important conclusions can be drawn. The failure of filgrastim to further accelerate myeloid reconstitution after high-dose chemotherapy and PBSC reinfusion resulted in similar morbidity, number of febrile days and antibiotic use in the two groups of patients (Table II) . Although most patients receiving filgrastim received fewer CFU-GM cells, all patients received numbers in excess of threshold values which produce optimal times to haemopoietic reconstitution. Our data failed to establish any correlation between numbers of CFU-GM cells reinfused above this level and the rate of subsequent haemopoietic reconstitution. There are obvious differences between the cost of the procedure in the two treatment cohorts. The overall cost of the procedure was calculated by adding costs of antibiotics, conditioning chemotherapy and cost of filgrastim to the bed cost per day of the in-patient stay after PBSC reinfusion. The major difference in cost of the procedure was due to the administration of filgrastim, which doubled procedural expense in the group receiving filgrastim after PBSC reinfusion. The period of hospitalisation and intensive support after myeloablative therapy was not influenced by the administration of CSFs. This study fails to support the value of routine administration of myeloid colony-stimulating factors after such therapy and has significant financial implications for centres carrying out high-dose chemotherapy.
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